Previous Close | 12.14 |
Open | 12.14 |
Bid | 7.50 |
Ask | 12.40 |
Strike | 5.00 |
Expire Date | 2024-10-18 |
Day's Range | 12.14 - 12.14 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Exploring the Financial Landscape and Strategic Progress Amidst Challenges
CAMBRIDGE, Mass., May 07, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024.
CAMBRIDGE, Mass., April 12, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purcha